公开(公告)号：US20220306698A1

公开(公告)日：2022-09-29

申请号：US17659007

申请日：2022-04-12

申请人： Exuma Biotech Corp.

发明人： Gregory Ian Frost ,  James Joseph Onuffer, Jr. ,  Ghiabe H. Guibinga ,  Farzad Haerizadeh ,  Frederic Vigant ,  Anirban Kundu

IPC分类号： C07K14/005 ,  C12N15/86 ,  C07K14/705 ,  C07K16/28 ,  C07K14/725 ,  C07K14/54 ,  A61K47/69 ,  A61K35/17 ,  C12N7/00

摘要： The present disclosure provides methods and compositions for genetically modifying lymphocytes, for example T cells and/or NK cells, in shorter times than previously and/or in whole blood or a component thereof. In some embodiments a lymphodepletion filter assembly is used before or after forming a reaction mixture where lymphocytes are contacted with recombinant retroviral particles in a closed system, to genetically modify the lymphocytes.

公开(公告)号：US20210107949A1

公开(公告)日：2021-04-15

申请号：US17110028

申请日：2020-12-02

申请人： Exuma Biotech Corp.

发明人： Gregory Ian Frost ,  James Joseph Onuffer ,  Ghiabe H. Guibinga ,  Farzad Haerizadeh ,  Frederic Vigant ,  Anirban Kundu

IPC分类号： C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  C07K14/705 ,  C07K16/28 ,  C07K14/725 ,  C07K14/54 ,  A61K47/69 ,  A61K35/17

摘要： The present disclosure provides methods and compositions for genetically modifying lymphocytes, for example T cells and/or NK cells, in shorter times than previously and/or in whole blood or a component thereof. In some embodiments a lymphodepletion filter assembly is used before or after forming a reaction mixture where lymphocytes are contacted with recombinant retroviral particles in a closed system, to genetically modify the lymphocytes.

公开(公告)号：US20230340536A1

公开(公告)日：2023-10-26

申请号：US18322531

申请日：2023-05-23

申请人： Exuma Biotech Corp.

发明人： Gregory Ian FROST ,  James Joseph ONUFFER, Jr. ,  Ghiabe H. Guibinga ,  Farzad HAERIZADEH ,  Anirban KUNDU

IPC分类号： C12N15/86 ,  A61K39/00 ,  C12N5/0783 ,  C07K14/005 ,  C07K14/715 ,  C07K14/705 ,  C07K16/30 ,  C07K14/725 ,  C12N15/113 ,  C12N15/10 ,  C07K16/32 ,  C07K14/54 ,  C07K16/28

CPC分类号： C12N15/86 ,  A61K39/0011 ,  C12N5/0646 ,  C07K14/005 ,  C07K14/7155 ,  C07K14/70596 ,  C07K16/30 ,  C07K14/7051 ,  C07K14/70578 ,  C07K14/70517 ,  C12N15/1138 ,  C12N15/1048 ,  C07K16/32 ,  C07K14/5418 ,  C07K16/2809 ,  C07K14/70521 ,  C12N5/0636 ,  C12N15/113 ,  C07K16/2803 ,  C07K16/2818 ,  C07K16/2863 ,  C07K16/283 ,  C12N2310/141 ,  C12N2760/18422 ,  C12N2740/10045 ,  C12N2840/203 ,  C12N2740/10043 ,  C12N2310/12 ,  C07K2319/02 ,  C12N2740/16043 ,  C12N2830/008 ,  C07K2319/31 ,  C12N2310/531 ,  C12N2510/00 ,  C12N2310/121 ,  C07K2319/33 ,  A61K35/17

摘要： The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells. The methods can include inhibitory RNA molecule(s) and/or engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and/or genetically modified T cells and/or NK cells are provided, such as, for example, those including riboswitches, MRB-CARs, recognition domains, and/or pH-modulating agents.

公开(公告)号：US20230257776A1

公开(公告)日：2023-08-17

申请号：US18301959

申请日：2023-04-17

申请人： Exuma Biotech Corp.

发明人： Gregory Ian FROST ,  James Joseph ONUFFER, Jr. ,  Ghiabe H. Guibinga ,  Farzad HAERIZADEH ,  Anirban KUNDU

IPC分类号： C12N15/86 ,  C12N15/113 ,  C07K14/725 ,  C07K14/705 ,  C07K16/30 ,  A61K39/00 ,  C07K16/28 ,  C12N5/0783 ,  C07K14/715 ,  C07K14/005 ,  C07K14/54 ,  C12N15/10 ,  C07K16/32

CPC分类号： C12N15/86 ,  C12N15/1138 ,  C07K14/7051 ,  C12N15/113 ,  C07K14/70517 ,  C07K16/30 ,  A61K39/0011 ,  C07K14/70596 ,  C07K16/2803 ,  C12N5/0646 ,  C07K14/70521 ,  C07K14/7155 ,  C07K14/005 ,  C12N5/0636 ,  C07K14/70578 ,  C07K14/5418 ,  C07K16/2809 ,  C07K16/2863 ,  C12N15/1048 ,  C07K16/2818 ,  C07K16/32 ,  C07K16/283 ,  C12N2740/10043 ,  C12N2830/002 ,  C12N2310/141 ,  C12N2740/10045 ,  C12N2310/121 ,  C07K2317/622 ,  C07K2319/03 ,  C07K2319/02 ,  A61K2039/5156 ,  A61K2039/572 ,  A61K35/17

摘要： The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells. The methods can include inhibitory RNA molecule(s) and/or engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and/or genetically modified T cells and/or NK cells are provided, such as, for example, those including riboswitches, MRB-CARs, recognition domains, and/or pH-modulating agents.

公开(公告)号：US11111505B2

公开(公告)日：2021-09-07

申请号：US15644778

申请日：2017-07-08

申请人： Exuma Biotech Corp.

发明人： Gregory Ian Frost ,  James Joseph Onuffer ,  Ghiabe H. Guibinga ,  Farzad Haerizadeh ,  Anirban Kundu

IPC分类号： C12N15/867 ,  C12N15/113 ,  C12N15/33 ,  C12N15/48 ,  C07K16/28 ,  C12N15/87 ,  A61K35/17 ,  A61K48/00 ,  C12N15/86 ,  C07K14/725 ,  C07K14/705 ,  C07K16/30 ,  A61K39/00 ,  C07K14/715 ,  C07K14/005

摘要： The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells. The methods can include inhibitory RNA molecule(s) and/or engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and/or genetically modified T cells and/or NK cells are provided, such as, for example, those including riboswitches, MRB-CARs, recognition domains, and/or pH-modulating agents.

公开(公告)号：US11325948B2

公开(公告)日：2022-05-10

申请号：US17110028

申请日：2020-12-02

申请人： Exuma Biotech Corp.

发明人： Gregory Ian Frost ,  James Joseph Onuffer, Jr. ,  Ghiabe H. Guibinga ,  Farzad Haerizadeh ,  Frederic Vigant ,  Anirban Kundu

IPC分类号： C12N15/867 ,  C07K14/005 ,  C12N15/86 ,  C07K14/705 ,  C07K16/28 ,  C07K14/725 ,  C07K14/54 ,  A61K47/69 ,  A61K35/17 ,  C12N7/00 ,  A61K38/00 ,  A61K39/00

摘要： The present disclosure provides methods and compositions for genetically modifying lymphocytes, for example T cells and/or NK cells, in shorter times than previously and/or in whole blood or a component thereof. In some embodiments a lymphodepletion filter assembly is used before or after forming a reaction mixture where lymphocytes are contacted with recombinant retroviral particles in a closed system, to genetically modify the lymphocytes.

公开(公告)号：US10596274B2

公开(公告)日：2020-03-24

申请号：US15462855

申请日：2017-03-19

申请人： Exuma Biotech Corp.

发明人： Gregory Ian Frost ,  James Joseph Onuffer ,  Ghiabe H. Guibinga

IPC分类号： C12N15/115 ,  A61K48/00 ,  C12N15/113 ,  C12N15/63 ,  C12N15/87 ,  C12N15/11 ,  C07K14/725 ,  C07K14/705 ,  C07K14/715 ,  C12N5/0783 ,  C12N15/10 ,  A61K35/17 ,  C07K14/005 ,  C07K14/54 ,  C07K16/28 ,  C07K16/30 ,  C12N7/00 ,  C12N15/86 ,  A61K39/00

摘要： The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells without prior ex vivo stimulation. The methods typically include engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted CAR. Additional elements of such engineered signaling polypeptides are provided herein, as well as vectors, such as retroviral vectors, packaging cell lines and methods of making the same. Furthermore, recombinant retroviruses and methods of making the same are provided. Numerous controls are provided, including riboswitches that are controlled, for example in vivo, by nucleoside analogues.